-
ALSO READ
Wall Street surges on hopes for stimulus, Covid-19 vaccine; Dow rises 3.2%
Wall Street slips as surging virus cases dent recovery hopes; Dow falls 1%
Wall Street jumps on Goldman's strong numbers, Covid-19 vaccine hopes
Wall Street gains on strong services sector data; Dow, S&P rise over 1%
Wall Street slumps on virus worries, grim economic forecast; Dow falls 2%
-
Wall Street’s main indexes fell on Tuesday with the S&P 500 and the Dow retreating from record closing highs hit a day earlier, following disappointing retail sales data and a spike in coronavirus cases across the country.
The Nasdaq’s losses were limited by a 12 per cent jump in Tesla Inc’s shares in anticipation of a $51 billion trade by index funds adjusting their holdings when the electric-car maker will be added to the benchmark S&P 500 in December.
The Dow notched an all-time closing high on Monday, finishing about 50 points shy of 30,000 after Moderna Inc’s promising COVID-19 vaccine data boosted hopes of an economic recovery, overshadowing spiking coronavirus cases across the country.
“There is conflict for the market between the near-term direction to the economy, which is troubled with the very high Covid-19 rates and the future for the market, that’s which vaccines could provide an end to the restrictions,” said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey.
New Jersey, California and Iowa imposed fresh restrictions as the pandemic reached its most perilous point yet in the United States, threatening to worsen as the colder weather sets in.
Latest data showed U.S. retail sales increased less than expected in October and could slow further due to spiraling new infections and a lack of fiscal support.
At 09:51 a.m. ET the Dow Jones Industrial Average fell 351.42 points, or 1.17 per cent, to 29,599.02, the S&P 500 lost 30.11 points, or 0.83 per cent, to 3,596.80 and the Nasdaq Composite lost 53.51 points, or 0.45 per cent, to 11,870.62.
Financials, industrials and energy stocks gave back some gains made over the last week as positive updates from U.S. vaccine trials encouraged investors to diversify into value stocks on hopes they will benefit from a pickup in the economy.
Amazon.com Inc rose 1.2 per cent after it launched an online pharmacy for delivering prescription medications in the United States. Drug retailers such as Walgreens Boots Alliance Inc tumbled 8.7 per cent, while CVS Health Corp fell 7.5 per cent on the news.
Warren Buffett’s Berkshire Hathaway Inc disclosed new stakes worth $5.7 billion in drugmakers Abbvie Inc, Bristol-Myers Squibb Co, Merck & Co and Pfizer Inc, lifting their shares between 1.4 per cent and 2.4 per cent.
Retail earnings is in focus this week as the third-quarter earnings season enters its tail end. Walmart Inc posted a bigger-than-expected increase in quarterly same-store sales. However, its shares fell 0.8 per cent after rallying 28 per cent this year.
Declining issues outnumbered advancers by 3.4-to-1 on the NYSE; on Nasdaq, a 0.3-to-1 ratio favored decliners.
The S&P 500 posted seven new 52-week highs and no new low, while the Nasdaq Composite recorded 49 new highs and three new lows.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU